By Serial Passage Of Virus Patents (Class 435/237)
  • Patent number: 9040296
    Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
    Type: Grant
    Filed: March 17, 2012
    Date of Patent: May 26, 2015
    Assignee: Valneva
    Inventors: Majid Mehtali, Patrick Champion-Arnaud, Arnaud Leon
  • Patent number: 9011876
    Abstract: The present invention features live, attenuated respiratory syncytial viruses (RSV) useful as vaccines against RSV infection and/or the development of severe RSV-associated illnesses. The disclosed viruses are attenuated to the extent of being nonpathogenic when administered to a subject but substantially retain the antigenic and immunogenic properties of wild-type RSV.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: April 21, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mary K. Yagodich, Michael P. Citron, Daniel J. Distefano, Daniel L. Krah, Xiaoping Liang
  • Patent number: 8852608
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: October 7, 2014
    Assignee: MedImmune, LLC
    Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, Joann Suzich
  • Patent number: 8815252
    Abstract: The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: August 26, 2014
    Assignee: Baxter Healthcare SA
    Inventors: Julia Romanova, Andrej Egorov, Brigitte Krenn, Markus Wolschek, Sabine Nakowitsch
  • Patent number: 8795688
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: August 5, 2014
    Assignees: Sanofi Pasteur, Centers for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Patent number: 8765136
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: July 1, 2014
    Assignee: MedImmune, LLC
    Inventors: Chin-Fen Yang, George Kemble, Kanta Subbarao, Brian Murphy
  • Patent number: 8748174
    Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: June 10, 2014
    Assignee: MedImmune, LLC
    Inventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
  • Patent number: 8691238
    Abstract: The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No. 1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: April 8, 2014
    Assignee: Baxter Healthcare SA
    Inventors: Thomas Muster, Markus Wolschek, Andrej Egorov, Elisabeth Roethl, Julia Romanova, Michael Bergmann
  • Publication number: 20130129762
    Abstract: The invention relates to a marker vaccine for prophylactic treatment of classical swine fever comprising modified live attenuated classical swine fever virus. The viral amino acid sequence of the TAV-epitope of the E2 protein comprises a different sequence from that of a wild-type classical swine fever virus. The invention relates to pharmaceutical compositions of the marker vaccine. The invention also relates to a method of manufacturing marker vaccines for prevention of classical swine fever using selective antibody pressure.
    Type: Application
    Filed: May 18, 2011
    Publication date: May 23, 2013
    Applicant: RIEMSER ARZNEIMITTEL AG
    Inventors: Martin Beer, Sandra Blome, Immanuel Leifer
  • Publication number: 20130089913
    Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.
    Type: Application
    Filed: November 29, 2012
    Publication date: April 11, 2013
    Applicant: BAVARIAN NORDIC A/S
    Inventor: BAVARIAN NORDIC A/S
  • Patent number: 8372622
    Abstract: The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: February 12, 2013
    Assignee: Bavarian Nordic A/S
    Inventors: Mark Suter, Sabine Vollstedt, Paul Chaplin
  • Publication number: 20120264616
    Abstract: The present invention concerns a method of directing evolution of a target polynucleotide of interest for obtaining variants of this target polynucleotide, as well as a method to generate genetic variability by preparing a cell library. This invention also relates to a method to isolate or to screen variants of a polynucleotide or variants of a protein able to impact the phenotype of a cell or to confer a desired phenotype to target cells, and to identify theses polynucleotide variants or protein variants responsible for this phenotype.
    Type: Application
    Filed: November 10, 2010
    Publication date: October 18, 2012
    Applicants: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Matteo Negroni, Sarah Gallois-Montbrun, Paola Rossolillo, Vincenzo Di Bartolo, Gilles Uze, Etienne Simon-Loriere, Roland Marquet, Valérie Vivet-Boudou
  • Publication number: 20120213810
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Application
    Filed: February 14, 2012
    Publication date: August 23, 2012
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, GMBH
    Inventors: Kim BURGARD, Jeremy KROLL, Sarah M. LAYTON, Volker OHLINGER, Francois-Xavier ORVEILLON, Stefan PESCH, Michael Dennis PIONTKOWSKI, Michael B. ROOF, Philip UTLEY, Eric Martin VAUGHN
  • Patent number: 8148132
    Abstract: The present invention relates to the development and manufacturing of viral vaccines, particularly the industrial production of viral vectors and vaccines, and more particularly the use of avian embryonic stem cells, preferably the EBx cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses; the invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: April 3, 2012
    Assignee: Vivalis
    Inventors: Majid Mehtali, Patrick Champion-Arnaud, Arnaud Leon
  • Patent number: 8142796
    Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: March 27, 2012
    Assignee: Bavarian Nordic A/S
    Inventors: Anton Mayr, Barbara Mayr
  • Patent number: 8119388
    Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: February 21, 2012
    Assignee: Medimmune, LLC
    Inventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
  • Publication number: 20120009654
    Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 12, 2012
    Inventors: Anton MAYR, Barbara MAYR
  • Publication number: 20110305726
    Abstract: The present invention relates to infectious bronchitis (IB) viruses derived from a recently identified genotype of IB virus known as IB-QX, or from viruses that are genetically related to IB-QX, herein referred to as IB-QX-like viruses. The IB viruses of the invention may be live and attenuated or inactivated. Live, attenuated IB viruses of the invention may be produced by serial passaging of an IB-QX-like virus. The IB viruses of the invention are useful for, inter alia, vaccines against IB-QX and IB-QX-like viruses. Heretofore, known vaccine strains of IB viruses have proven insufficient to protect against infectious bronchitis caused by IB-QX and IB-QX-like viruses.
    Type: Application
    Filed: August 7, 2009
    Publication date: December 15, 2011
    Applicant: Wyeth LLC
    Inventors: Harmen Jacob Geerligs, Cindy Aleida Maria Meinders, Geert Jan Boelm, Bastiana Geertruida Elisabeth Stuurman
  • Patent number: 8034356
    Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: October 11, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Anton Mayr, Barbara Mayr
  • Patent number: 7939085
    Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: May 10, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Anton Mayr, Barbara Mayr
  • Publication number: 20100215691
    Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Application
    Filed: February 19, 2010
    Publication date: August 26, 2010
    Inventors: Christopher L. PARKS, Ivo Lorenz, Sanjay K. Phogat, Timothy J. Zamb
  • Patent number: 7670837
    Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: March 2, 2010
    Assignee: Medimmune, LLC
    Inventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
  • Publication number: 20090175906
    Abstract: The present invention relates to methods for generating genetically modified and attenuated strains of vesicular stomatitis virus (VSV) for use in the preparation of immunogenic compositions. More particularly, the invention relates to the identification of particular genetic modifications of attenuated VSV that result in an increased yield of virus and an increase in stability of the attenuated strains for preparation of the immunogenic compositions. Methods for cell culture propagation and use in large scale production of VSV is also disclosed.
    Type: Application
    Filed: December 18, 2008
    Publication date: July 9, 2009
    Applicant: Wyeth
    Inventors: Narender Kumar Kalyan, Irina Yurgelonis, Roger Michael Hendry, Mark William Cutler, Kristen Elissa Syvertsen
  • Publication number: 20090162918
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Application
    Filed: November 1, 2007
    Publication date: June 25, 2009
    Inventors: Andre Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, Francois Madec
  • Patent number: 7494799
    Abstract: The invention relates to monoparamunity inducers that are based on paramunizing viruses or viral components of a myxoma virus strain of diseased rabbits that show general symptoms of the disease. The invention also relates to a method for producing the inducers and to their use as drugs for the regulatory optimization of the paramunizing activities for use in the prophylaxis and therapy of various human and animal dysfunctions.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: February 24, 2009
    Assignee: Bavarian Nordic A/S
    Inventors: Anton Mayr, Barbara Mayr
  • Patent number: 7465580
    Abstract: The invention provides a vector encoding a derivative of EBNA-1 that is not cytotoxic when expressed efficiently in cells, which supports extrachromosomal replication, maintenance and transcription from extrachromosomal oriP containing vectors but does not substantially activate transcription from host cell genes. Also provided is a vector having oriP and encoding a derivative of EBNA-1. The vectors of the invention may be employed in vitro and in gene therapy.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: December 16, 2008
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: William M. Sugden, Jindong Wang, Gregory Dean Kennedy
  • Patent number: 7384644
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by induction of protective immunity against a lethal vaccinia virus infection in a mouse, whereby the effective amount of the MVA-BN virus, or a derivative thereof, required to confer said immunity is less than the effective amount of MVA-575 required to render said mouse immune to a lethal vaccinia virus infection, and/or the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: June 10, 2008
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel
  • Patent number: 7344723
    Abstract: A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV RNA in cell culture. This self-replicating polynucleotide molecule contains, contrary to all previous reports, a 5?-NTR that can be either an A as an alternative to the G already disclosed and therefore provides an alternative to existing systems comprising a self-replicating HCV RNA molecule. The G-->A mutation gives rise to HCV RNA molecules that, in conjunction with mutations in the HCV non-structural region, such as the G(2042)C/R mutations, possess greater efficiency of transduction and/or replication. These RNA molecules when transfected in a cell line are useful for evaluating potential inhibitors of HCV replication.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: March 18, 2008
    Assignee: Boehringer Ingelheim (Canada) Ltd.
    Inventors: George Kukolj, Arnim Pause
  • Publication number: 20080019945
    Abstract: A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes.
    Type: Application
    Filed: December 20, 2006
    Publication date: January 24, 2008
    Applicant: Medlmmune Vaccines, Inc.
    Inventors: George Kemble, Gregory M. Duke, Richard Spaete
  • Patent number: 7309493
    Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: December 18, 2007
    Assignee: Novartis AG
    Inventors: Kelly Knape, Stephanie Dykstra, Mary Tinant
  • Patent number: 7291342
    Abstract: Embodiments of the present invention generally relate to a novel attenuated infectious bronchitis virus (IBV) of GA-98 isolate. Further, other embodiments of the present invention generally relate to methods of immunizing avian against an infectious bronchitis virus. As well, further embodiments relate to method of making a vaccine and/or immunogenic composition for protecting avian, such as poultry, from an infectious bronchitis virus of strain GA-98.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: November 6, 2007
    Assignee: Intervet International B.V.
    Inventors: Lillian Melson, Faris Jirjis
  • Patent number: 7235393
    Abstract: A method for isolating AAV viruses from cellular DNA of non-human primate (NHP) tissues by transfecting the DNA of NHP into 293 cells, rescuing the virus and amplifying it through serial passages in the presence of adenovirus helper functions is provided. Also provided are kits useful for performing this method.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: June 26, 2007
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 7189536
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: March 13, 2007
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger
  • Patent number: 7150984
    Abstract: The present invention provides vaccine compositions of attenuated human rotavirus. More particularly, the attenuated human rotavirus is produced by cold passage and thus contains attenuating mutations which produce virus having a cold-adapted (ca) and temperature sensitive (ts) phenotype. The attenuated strains are used in methods for stimulating the immune system of an individual to induce protection against human rotavirus by administration of the ca attenuated rotavirus.
    Type: Grant
    Filed: July 11, 1995
    Date of Patent: December 19, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Yasutaka Hoshino, Albert Z. Kapikian, Robert M. Chanock
  • Patent number: 7037508
    Abstract: The present invention is directed to attenuated pestivirus mutants, which have a reduced ability to replicate as exhibited by a small plaque size. The mutations are in the 5? nontranslated region of the viral genome. These mutant viruses are useful as live vaccines in the control of bovine viral diarrhea, border disease and classical swine fever.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: May 2, 2006
    Assignee: Akzo Nobel NV
    Inventors: Heinz-Jürgen Thiel, Paul P. Becher, Michaela M. Orlich
  • Patent number: 7029682
    Abstract: Immunogenic preparations and vaccines, in particular which are inactivated, effective against feline calicivirosis, based on an FCV virus strain 431 as deposited at the CNCM under the accession number CNCM I-2166, or one of its equivalents, in a veterinarily acceptable vehicle or excipient, preferably combined with FCV virus obtained from another FCV strain, in particular strain G1 as deposited at the CNCM under the accession number CNCM I-2167.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: April 18, 2006
    Assignee: Merial
    Inventors: Herve Poulet, Sylvian Gabriel Goutebroze
  • Patent number: 6982160
    Abstract: The invention includes kits for producing and using immunogenic compositions that include swine infertility and respiratory virus. The invention also includes vaccines and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: January 3, 2006
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
  • Patent number: 6974577
    Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.
    Type: Grant
    Filed: February 4, 2001
    Date of Patent: December 13, 2005
    Assignee: Novartris AG
    Inventors: Kelly Knape, Stephanie Dykstra, Mary Tinant
  • Patent number: 6946136
    Abstract: The present invention relates to isolated, attenuated viral strains of human parainfluenza virus 2 (HPIV-2), which are useful in live vaccine preparations. These strains exhibit a temperature sensitive and cold adapted phenotype useful for stimulating a protective immune response in an inoculated mammal without producing severe symptoms.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: September 20, 2005
    Assignee: St. Louis University
    Inventors: Robert B. Belshe, Frances K. Newman
  • Patent number: 6852522
    Abstract: The present invention relates, to novel methods and substrates for the propagation of viruses. The invention relates to IFN-deficient substrates and methods for propagating viruses in these unconventional substrates. In particular, the invention relates to methods of propagating viruses in immature embryonated eggs, preferably six- to nine-day-old chicken eggs. The methods of the invention are particularly attractive for growing viruses suitable for use in vaccine and pharmaceutical formulations.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 8, 2005
    Assignee: Mount Sinai School of Medicine of New York University
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Robert O'Neil
  • Patent number: 6833133
    Abstract: A vaccine against Newcastle Disease contains one or more mutant immunogens of the NDW strain. The mutant immunogen lacks the antigenic binding site on the F glycoprotein which is recognized by the monoclonal antibody mAb 54. Reagent kits and assay methods help to distinguish vaccinated members of a poultry flock from those that may have been infected with wild-type Newcastle Disease virus.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: December 21, 2004
    Assignee: Wyeth
    Inventors: Harmen J. Geerligs, Ian Hamer Brown, Dennis John Alexander, Michael Sinclair Collins
  • Patent number: 6803041
    Abstract: A vaccine for protecting a horse against diseases associated with EHV-1 and/or EHV-4 is provided. The vaccine commonly includes inactivated EHV-1 (e.g., chemically inactivated EHV-1 KyA virus) and an adjuvant. The adjuvant can include a cross-linked olefinically unsaturated carboxylic acid polymer which may have bioadhesive properties. The vaccine may also include antigens against other equine pathogens such as inactivated EHV-4 and inactivated A1 and/or A2 strains of equine influenza virus. Methods for protecting horses against diseases associated with EHV-1 and/or EHV-4 and methods of producing the equine herpesvirus vaccine are also provided.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: October 12, 2004
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventor: Mark W. Mellencamp
  • Patent number: 6761893
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: July 13, 2004
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger
  • Patent number: 6682743
    Abstract: The invention provides new strains of the Modified Vaccinia Virus Ankara (MVA) that have a strongly reduced virulence for most mammals, especially humans, but nevertheless grows in cells of a continuous cell line approved for the production of a therapeutic agent such as a vaccine. The invention also provides a method for producing said adapted MVA strains. The adapted MVA can be used e.g. for parenteral immunization, as a vector system, or in the active or inactivated from as an adjuvant or as a regulator of the unspecific components of the immune system.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: January 27, 2004
    Assignee: Bavarian Nordic A/S
    Inventor: Anton Mayr
  • Patent number: 6660272
    Abstract: The invention relates to new porcine circovirus strains isolated from pulmonary or ganglionic samples obtained from farms affected by the post-weaning multisystemic wasting syndrome (PMWS). It relates to purified preparations of these strains, conventional attenuated or inactivated vaccines, recombinant live vaccines, plasmid vaccines and subunit vaccines, as well as reagents and diagnostic methods. It also relates to the DNA fragments which can be used for the production of subunits in an in vitro expression vector or as sequences to be integrated into a virus or plasmid type in vivo expression vector.
    Type: Grant
    Filed: June 19, 2001
    Date of Patent: December 9, 2003
    Assignees: Merial, The Queen's University of Belfast, University of Saskatchewan
    Inventors: Gordon Allan, Brian Meehan, Edward Clark, John Ellis, Deborah Haines, Lori Hassard, John Harding, Catherine Elisabeth Charreyre, Gilles Emile Chappuis, Francis McNeilly
  • Patent number: 6649169
    Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: November 18, 2003
    Assignee: The University of Pittsburgh of the Commonwealth System of Higher Education
    Inventors: Patricia W. Dowling, Julius S. Youngner
  • Patent number: 6632647
    Abstract: The present invention relates to the use, in humans, of inactivated parapoxviruses for the prophylaxis and treatment of diseases which are accompanied by an increased deposition of collagen, with it being possible for both internal organs, such as the liver, and the skin and its appended structures, to be affected. The invention relates, in particular, to liver fibrosis and/or liver cirrhosis consequent upon virus hepatitis, or to ethanol-induced liver diseases and to cystic fibrosis.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: October 14, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Claudia Hirth-Dietrich, Tobias Schlapp, Angela Siegling, Andreas Knorr, Olaf Weber, Gudrun Theiss
  • Patent number: 6605460
    Abstract: Compositions and methods for ameliorating the clinical signs of an avian pneumovirus infection in a bird are disclosed. The compositions include immunologically effective amounts of an attenuated or inactivated avian pneumovirus. Methods for preparing an attenuated avian pneumovirus composition are also described.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: August 12, 2003
    Assignee: University of Minnesota
    Inventor: Sagar M. Goyal
  • Publication number: 20030108860
    Abstract: The present invention provides improved methods of production of viral antigen on a culture of adherent cells bound to a microcarrier, wherein the methods provide for increased viral antigen yield per culture medium volume. The invention is also directed to a cell culture biomass of adherent cells having increased cell density and microcarrier concentration compared to the respective confluent cell culture.
    Type: Application
    Filed: December 10, 2001
    Publication date: June 12, 2003
    Inventors: Manfred Reiter, Wolfgang Mundt
  • Patent number: RE39494
    Abstract: The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The resulting bacterin and adjuvant mixture can also be mixed with other bacteria such as Bordetella and Pasteurella, for further adjuvant effect. Protective immunity against mycoplasmal pneumonia is elicited in swine using these vaccines.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: February 27, 2007
    Assignee: Intervet Inc.
    Inventors: Gerald R. Fitzgerald, C. Joseph Welter